We conducted a systematic review according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (see Supplementary Material A) [8], aiming to evaluate the reported activity of ALK-i in ALK-RCC patients published in the scientific literature. Here, ALK is linked to renal cell adenocarcinoma.